US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Qiagen N.V. Common Shares (NY:QGEN)

45.79 +1.04 (+2.32%)
Official Closing Price Updated: 7:00 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Qiagen N.V. Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Will Investors Notice Exciting Sign On Qiagen's Chart? ↗
 
Via Benzinga
News headline image
QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics’ KRAZATI in non-small cell lung cancer
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN launches monkeypox test for NeuMoDx platform to fight global outbreak by boosting research and surveillance
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches Syndromic Test For QIAstat-Dx For Six Pathogens Similar To Monkeypox ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 7, 2022 ↗
Companies Reporting Before The Bell • NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million. 
Via Benzinga
News headline image
A Preview Of Qiagen's Earnings ↗
Qiagen (NYSE:QGEN) is set to give its latest quarterly earnings report on Monday, 2022-11-07. Here's what investors need to know before the announcement. Analysts estimate that Qiagen will report an... 
Via Benzinga
News headline image
QIAGEN N.V. to Release Results for Q3 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely ↗
One analyst doubts any deal could come to fruition. If it did, it would make sense. 
Via Investor's Business Daily
News headline image
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11 ↗
Reuters US-China Chip War: KLA Relaxes Chip Supply To China 
Via Benzinga
News headline image
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals ↗
Bio-Rad Laboratories Inc (NYSE: BIO) is reportedly in talks to merge with Qiagen NV (NYSE: QGEN), but any agreement isn't likely for another few weeks or more, or it may not happen at all. 
Via Benzinga
News headline image
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests ↗
 
Via Benzinga
News headline image
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns ↗
The World Health Organization (WHO) warned that it struggles to identify and 
Via Benzinga
News headline image
IGI Inex Holding (UK) Becomes Strategic Investor in Quantumrock, Cementing Partnership Between Leading Global Investment Group and AI Asset Tech Frontrunners
Via ACCESSWIRE
News headline image
QIAGEN Adds New Assays With CE-IVD Certification for NeuMoDx Integrated PCR System
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN and Neuron23 Partner to Develop Next-Generation Sequencing Companion Diagnostic for Novel Parkinson’s Disease Drug
From QIAGEN N.V.
Via Business Wire
News headline image
No More Free COVID-19 At-Home Tests, Federal Government Says ↗
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au 
Via Benzinga
News headline image
QIAGEN Issues 2021 Sustainability Report
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Launches Syndromic Test for QIAstat-Dx Device to Combat Global Monkeypox Health Emergency
From QIAGEN N.V.
Via Business Wire
News headline image
Qiagen Posts Robust Q2 Non-COVID Sales Growth, Lifts Annual Guidance ↗
Qiagen N.V. (NYSE: QGEN) clocked Q2 FY22 revenues of $516 million, down 9% Y/Y, well above the consensus of $488.73 million. 
Via Benzinga
News headline image
QIAGEN adds new biopharma products to QIAcuity digital PCR portfolio and launches Expert Custom Assay Design Service
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN beats outlook for Q2 2022 and raises full-year 2022 outlook
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Clinical Decision Support Platform QCI Surpasses Three Million NGS Patient Test Cases
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN N.V. to Release Results for Q2 2022 and Hold Webcast
From QIAGEN N.V.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, investor! We're back with a breakdown of the biggest pre-market stock movers for Tuesday to get the day started! 
Via InvestorPlace
News headline image
U.S. CDC Endorses the Use of Digital PCR Technology for Wastewater Surveillance of Infectious Diseases – Including COVID-19 Outbreaks
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN’s Eco-Friendlier Products Earn Prestigious ACT Label
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Expands Syndromic Testing Portfolio with the Launch of Higher-Capacity QIAstat-Dx Rise and Enhanced Panels
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Acquires Majority Stake in Enzymes Provider BLIRT S.A.
From QIAGEN N.V.
Via Business Wire
News headline image
QIAGEN Proposes Expansion of Supervisory Board
From QIAGEN N.V.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >